Fortress Biotech, Inc develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$26.88 million
Profitability
Miscellaneous
Employees68
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions
What is Fortress Biotech's stock symbol?
Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."
How were Fortress Biotech's earnings last quarter?
Fortress Biotech (NASDAQ:FBIO) released its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.22. The biopharmaceutical company earned $9.25 million during the quarter, compared to analyst estimates of $7.51 million. View Fortress Biotech's Earnings History.
When is Fortress Biotech's next earnings date?
What price target have analysts set for FBIO?
2 brokerages have issued 12-month price targets for Fortress Biotech's stock. Their forecasts range from $4.00 to $11.00. On average, they anticipate Fortress Biotech's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 365.8% from the stock's current price. View Analyst Price Targets for Fortress Biotech.
What is the consensus analysts' recommendation for Fortress Biotech?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fortress Biotech.
What are Wall Street analysts saying about Fortress Biotech stock?
Here are some recent quotes from research analysts about Fortress Biotech stock:
- 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (7/15/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/13/2019)
Has Fortress Biotech been receiving favorable news coverage?
Media headlines about FBIO stock have trended positive on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fortress Biotech earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Fortress Biotech.
Are investors shorting Fortress Biotech?
Fortress Biotech saw a increase in short interest in July. As of July 31st, there was short interest totalling 1,461,200 shares, an increase of 19.6% from the June 30th total of 1,221,700 shares. Based on an average daily volume of 392,300 shares, the days-to-cover ratio is presently 3.7 days. Approximately 4.4% of the company's stock are sold short. View Fortress Biotech's Current Options Chain.
Who are some of Fortress Biotech's key competitors?
Some companies that are related to Fortress Biotech include Intra-Cellular Therapies (ITCI), Syros Pharmaceuticals (SYRS), Magenta Therapeutics (MGTA), Aptorum Group (APM), Sinovac Biotech (SVA), Advanz Pharma (CXRXF), Milestone Pharmaceuticals (MIST), Urogen Pharma (URGN), Dova Pharmaceuticals (DOVA), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Flexion Therapeutics (FLXN), BioSpecifics Technologies (BSTC), CytomX Therapeutics (CTMX) and Evolus (EOLS).
What other stocks do shareholders of Fortress Biotech own?
Who are Fortress Biotech's key executives?
Fortress Biotech's management team includes the folowing people:
- Dr. Lindsay Allan Rosenwald, Exec. Chairman, Pres & CEO (Age 64)
- Dr. Eric K. Rowinsky, Co-Vice Chairman & Consultant (Age 62)
- Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. (Age 53)
- Ms. Robyn M. Hunter, CFO, Treasurer & Corp. Sec. (Age 57)
- Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 65)
Who are Fortress Biotech's major shareholders?
Fortress Biotech's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.24%), BlackRock Inc. (0.66%), Northern Trust Corp (0.65%), Acadian Asset Management LLC (0.34%), Paloma Partners Management Co (0.24%) and FNY Investment Advisers LLC (0.21%). Company insiders that own Fortress Biotech stock include George Avgerinos, Lindsay A Md Rosenwald and Robyn Hunter. View Institutional Ownership Trends for Fortress Biotech.
Which institutional investors are selling Fortress Biotech stock?
FBIO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have sold Fortress Biotech company stock in the last year include George Avgerinos and Robyn Hunter. View Insider Buying and Selling for Fortress Biotech.
Which institutional investors are buying Fortress Biotech stock?
FBIO stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Paloma Partners Management Co, FNY Investment Advisers LLC, Jane Street Group LLC, Acadian Asset Management LLC, Weiss Asset Management LP, A.R.T. Advisors LLC and Candriam Luxembourg S.C.A.. View Insider Buying and Selling for Fortress Biotech.
How do I buy shares of Fortress Biotech?
Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fortress Biotech's stock price today?
One share of FBIO stock can currently be purchased for approximately $1.61.
How big of a company is Fortress Biotech?
Fortress Biotech has a market capitalization of $111.15 million and generates $26.88 million in revenue each year. The biopharmaceutical company earns $-84,150,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.View Additional Information About Fortress Biotech.
What is Fortress Biotech's official website?
How can I contact Fortress Biotech?
Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Fortress Biotech (NASDAQ FBIO)
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
